- Endo International Plc ENDP initiated negotiations with its lenders and senior bondholders regarding a possible reorganization of more than $8 billion of its debt, the Wall Street Journal reported, citing people familiar with the matter.
- Lenders began talks after the company reported disappointing earnings early this month for 1Q 2022, driven by the loss of exclusive rights to a key drug.
- Related: Endo Shares Plummet On Decreasing Sales, Wider Loss; Outlook Lagging Consensus.
- The lawyers representing lenders have already started the confidential discussions with the company.
- Endo is already battling roughly 3,500 lawsuits over its role in the opioid epidemic.
- Also Read: JNJ, McKesson, Endo Settle $275M Opioid Claims With Alabama: Reuters.
- Price Action: ENDP shares are down 48.1% at $0.60 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareLegalMoversMediaTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in